Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The 5 Modifying Factors of Concussion
Neuro Trauma, Critical Care, and Sports Neurology
P10 - Poster Session 10 (5:30 PM-6:30 PM)
5-007

The goal of this study was to examine if patients with longer time to recovery (TTR) express distinct symptomology of five specific modifying concussion variables (MCVs).
 There have been few studies on the clinical interview of concussion. Symptoms reported by patients reflect underlying pathology of concussion. Several concussion symptom checklists exist. This study aims to provide a concise symptom assessment to aid in assessing TTR.
A retrospective review of 1,182 concussion patients, from January 2012 to June 2019. After exclusion criteria, 867 (73.3%) patients aged 1-78 years qualified (patients in litigation were excluded).  This study examined five commonly reported MCVs (headache, dizziness, attention/concentration dysfunction, sleep disturbance, and mood disturbance) evaluated at the initial clinical interview. The number of MCVs, types of MCVs, demographics, and past medical history were analyzed as they relate to TTR.
The median TTR for the entire patient population was 163 days (95% CI: 141, 209) with 65% of patients reporting complete recovery after one year and 75% after two years. Median TTR for pediatric patients was 66 days, 115 days for adolescents, and 570 days for adults. Multivariate analyses revealed increasing age (P <0.0001), number of MCVs (P<0.0001), moodiness (P < 0.0001), sleep disturbance (P <0.0001), and ADHD history (P=0.0006) were significantly associated with prolonged recovery. Female gender was associated with an increased likelihood of reporting more symptoms, therefore correlating with longer TTR (P= 0.0148).
An evaluation of five MCVs in a specialized outpatient concussion clinic showed that specific variables impact TTR. In particular, mood and sleep disturbances were associated with prolonged TTR as well as increased number of symptoms and increasing age.
Authors/Disclosures
Said Shukri, MD (University of Michigan)
PRESENTER 		Dr. Shukri has nothing to disclose.
Michael Lillis, Jr., LMHC (Dent Neurologic Institute) No disclosure on file
Dilpreet Kaur-Spencer, MD (Madigan Army Medical Center - JBLM) No disclosure on file
Rebecca A. Burgos (Dent Neurologic Institute) No disclosure on file
Patrick Eugeni (1998) Mr. Eugeni has nothing to disclose.
Brianna Albert, DO (Boston Children's Hospital) No disclosure on file
Jennifer W. McVige, MD, FÂ鶹´«Ã½Ó³»­ (Dent Neurological Institute) Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. McVige has received research support from Amgen. The institution of Dr. McVige has received research support from Eli Lily. The institution of Dr. McVige has received research support from Biohaven/Pfizer. The institution of Dr. McVige has received research support from Lundbeck. The institution of Dr. McVige has received research support from Dent Family Foundation. The institution of Dr. McVige has received research support from Abbvie. The institution of Dr. McVige has received research support from Teva. The institution of Dr. McVige has received research support from Theranica. Dr. McVige has a non-compensated relationship as a Neurology Board with UCNS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. McVige has a non-compensated relationship as a Board Exam Board Member with ABPN that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.